| Perspective and costing in cost-effectiveness analysis, 1974–2018 DD Kim, MC Silver, N Kunst, JT Cohen, DA Ollendorf, PJ Neumann Pharmacoeconomics 38, 1135-1145, 2020 | 186 | 2020 |
| Calculating the expected value of sample information in practice: considerations from 3 case studies A Heath, N Kunst, C Jackson, M Strong, F Alarid-Escudero, ... Medical Decision Making 40 (3), 314-326, 2020 | 43 | 2020 |
| Computing the expected value of sample information efficiently: practical guidance and recommendations for four model-based methods N Kunst, ECF Wilson, D Glynn, F Alarid-Escudero, G Baio, A Brennan, ... Value Health 23 (6), 734-742, 2020 | 42* | 2020 |
| A value of information analysis of research on the 21-gene assay for breast cancer management NR Kunst, F Alarid-Escudero, AD Paltiel, SY Wang Value in Health 22 (10), 1102-1110, 2019 | 25 | 2019 |
| Cost-effectiveness of neoadjuvant-adjuvant treatment strategies for women with erbb2 (her2)–positive breast cancer N Kunst, SY Wang, A Hood, SS Mougalian, MP DiGiovanna, K Adelson, ... JAMA network open 3 (11), e2027074-e2027074, 2020 | 20 | 2020 |
| Estimating population-based recurrence rates of colorectal cancer over time in the United States N Kunst, F Alarid-Escudero, E Aas, VMH Coupé, D Schrag, KM Kuntz Cancer Epidemiology, Biomarkers & Prevention 29 (12), 2710-2718, 2020 | 19 | 2020 |
| Use and costs of breast cancer screening for women in their 40s in a US population with private insurance N Kunst, JB Long, X Xu, SH Busch, KA Kyanko, IB Richman, CP Gross JAMA Internal Medicine 180 (5), 799-801, 2020 | 17 | 2020 |
| Simulating study data to support expected value of sample information calculations: a tutorial A Heath, M Strong, D Glynn, N Kunst, NJ Welton, JD Goldhaber-Fiebert Medical Decision Making 42 (2), 143-155, 2022 | 15 | 2022 |
| Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia G Goshua, P Sinha, N Kunst, L Pischel, AI Lee, A Cuker American journal of hematology 98 (1), 122-130, 2023 | 11 | 2023 |
| Emerging therapies for COVID-19: the value of information from more clinical trials SW Dijk, EM Krijkamp, N Kunst, CP Gross, JB Wong, MGM Hunink Value in Health 25 (8), 1268-1280, 2022 | 11 | 2022 |
| Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research N Kunst, NK Stout, G O’Brien, KD Christensen, PM McMahon, AC Wu, ... JNCI: Journal of the National Cancer Institute 114 (5), 722-731, 2022 | 10 | 2022 |
| Cost-effectiveness of nivolumab plus ipilimumab with and without chemotherapy for advanced non-small cell lung cancer SC Yang, N Kunst, CP Gross, JD Wang, WC Su, SY Wang Frontiers in oncology 11, 760686, 2021 | 9 | 2021 |
| Consolidated Health Economic Evaluation Reporting Standards-Value of Information (CHEERS-VOI): Explanation and Elaboration N Kunst, A Siu, M Drummond, SE Grimm, J Grutters, D Husereau, ... Value in Health 26 (10), 1461-1473, 2023 | 8 | 2023 |
| Treatment sequencing patterns and associated direct medical costs of metastatic breast cancer care in the United States, 2011 to 2021 RJ Chehayeb, A Hood, X Wang, R Miksad, SS Mougalian, MB Lustberg, ... JAMA network open 5 (11), e2244204-e2244204, 2022 | 7 | 2022 |
| Comparative effectiveness of digital breast tomosynthesis for breast cancer screening among women 40-64 years old IB Richman, JB Long, JR Hoag, A Upneja, R Hooley, X Xu, N Kunst, ... JNCI: Journal of the National Cancer Institute 113 (11), 1515-1522, 2021 | 7 | 2021 |
| A review of web-based tools for value-of-information analysis H Tuffaha, C Rothery, N Kunst, C Jackson, M Strong, S Birch Applied health economics and health policy 19, 645-651, 2021 | 7 | 2021 |
| The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial T Knauss, BT Hansen, K Pedersen, G Aasbø, N Kunst, EA Burger Gynecologic oncology 168, 39-47, 2023 | 6 | 2023 |
| A guide to an iterative approach to model-based decision making in health and medicine: an iterative decision-making framework N Kunst, EA Burger, VMH Coupé, KM Kuntz, E Aas Pharmacoeconomics 42 (4), 363-371, 2024 | 5 | 2024 |
| CHEERS value of information (CHEERS-VOI) reporting standards–explanation and elaboration N Kunst, A Siu, M Drummond, S Grimm, J Grutters, D Husereau, ... Value in Health, 2023 | 5 | 2023 |
| Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018 DD Kim, MC Silver, N Kunst, JT Cohen, DA Ollendorf, PJ Neumann Pharmacoeconomics 38, 1377-1377, 2020 | 5 | 2020 |
